BioSpace News Archive

Compugen Ltd., a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced that management will present at the following upcoming virtual investor conferences

Valeo Pharma Inc., a Canadian specialty pharmaceutical company, announced that it has received a Natural Product Licence approval from Health Canada authorizing the sale of its bioflavonoid formulation, HespercoTM, in Canada.

CANTEL MEDICAL CORP. will release the results for its fourth quarter ended July 31, 2020 on Thursday, September 17, 2020 before the market opens, and hold a conference call to discuss the results at 8:30 a.m. ET.

Sutro Biopharma, Inc. announced that Bill Newell, Chief Executive Officer, will present at the following investor conferences in September

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announces top-line results from PRO2TECT, the second of its two global Phase 3 cardiovascular outcomes programs.

Boston Scientific announced that the U.S. Centers for Medicare and Medicaid Services granted a New Technology Add-on Payment for the Eluvia™ Drug-Eluting Vascular Stent System as part of the 2021 Inpatient Prospective Payment System.

Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced that management will participate in the following virtual investor conferences in September:

Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, announced that it has appointed Helen M. Boudreau, former Chief Operating Officer of the Bill & Melinda Gates Medical Research Institute, to its Board of Directors.

Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that the Company will participate in the following upcoming investor conferences: Citi’s 15th Annual BioPharma Virtual Conference: Frank DeRosa, Chief Technology Officer, will participate in a panel discussing COVID-

Urothelial carcinoma, also known as transitional cell carcinoma, is a cancerous tumor of the bladder which can spread to other parts of the body.